EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations

被引：164

作者：

Thunnissen, Erik ^{[1
]}

Bubendorf, Lukas ^{[2
]}

Dietel, Manfred ^{[3
]}

Elmberger, Goran ^{[4
]}

Kerr, Keith ^{[5
]}

Lopez-Rios, Fernando ^{[6
]}

Moch, Holger ^{[7
]}

Olszewski, Wlodzimierz ^{[8
]}

Pauwels, Patrick ^{[9
]}

Penault-Llorca, Frederique ^{[10
]}

Rossi, Giulio ^{[11
]}

机构：

[1] Vrije Univ Amsterdam, Dept Pathol, Med Ctr, Amsterdam, Netherlands

[2] Univ Basel Hosp, Inst Pathol, CH-4031 Basel, Switzerland

[3] Charite, Inst Pathol, Berlin, Germany

[4] Karolinska Univ Hosp, Dept Pathol, Stockholm, Sweden

[5] Univ Aberdeen, Dept Pathol, Sch Med, Aberdeen, Scotland

[6] Hosp Univ Sanchinarro, Lab Dianas Terapeut, Ctr Integral Oncol, Madrid, Spain

[7] Univ Spital Zurich, Inst Surg Pathol, Zurich, Switzerland

[8] Maria Sklodowska Curie Inst Oncol, Dept Pathol, Warsaw, Poland

[9] Univ Antwerp Hosp, Dept Pathol, Edegem, Belgium

[10] Ctr Jean Perrin, Dept Pathol, Clermont Ferrand, France

[11] Azienda Policlin Modena, Sez Anat Patol, Modena, Italy

来源：

VIRCHOWS ARCHIV | 2012年 / 461卷 / 03期

关键词：

Anaplastic lymphoma kinase; Rearrangement; Crizotinib; Algorithm; Guidelines; Non-small cell lung cancer; IN-SITU-HYBRIDIZATION; ALK GENE REARRANGEMENT; ANAPLASTIC LYMPHOMA; FUSION GENE; C-MET; KINASE; CANCER; INHIBITOR; ADENOCARCINOMA; TRANSLOCATION;

D O I：

10.1007/s00428-012-1281-4

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

In non-small cell lung cancer, epidermal growth factor receptor gene mutations and anaplastic lymphoma kinase (ALK) gene rearrangements have a major impact upon the level of response to treatment with specific tyrosine kinase inhibitors. This review describes the molecular basis of ALK inhibition, summarizes current data on the effectiveness and safety of ALK inhibition therapy, describes the different testing methodologies with their advantages and disadvantages, provides a suggested testing algorithm and puts forward a proposal for an external quality assessment program in ALK testing.

引用

页码：245 / 257

页数：13

共 66 条

[1]

[Anonymous], NCCN FLASH UPD NCCN

[2] Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues:: Variation in staining intensity due to choice of fixative and storage time of tissue sections [J].

Atkins, D ;

Reiffen, KA ;

Tegtmeier, CL ;

Winther, H ;

Bonato, MS ;

Störkel, S .

JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2004, 52 (07) :893-901

[3] Heterogeneous HER2 Gene Amplification Impact on Patient Outcome and a Clinically Relevant Definition [J].

Bartlett, Alastair I. ;

Starcyznski, Jane ;

Robson, Tammy ;

MacLellan, Alex ;

Campbell, Fiona M. ;

van de Vekle, Cornelis J. H. ;

Hasenburg, Annette ;

Markopoulos, Christos ;

Seynaeve, Caroline ;

Rea, Daniel ;

Bartlett, John M. S. .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2011, 136 (02) :266-274

[4] HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods [J].

Bartlett, J. M. S. ;

Starczynski, J. ;

Atkey, Neil ;

Kay, E. ;

O'Grady, A. ;

Gandy, Michael ;

Ibrahim, Merdol ;

Jasani, Bharat ;

Ellis, I. O. ;

Pinder, S. E. ;

Walker, R. A. .

JOURNAL OF CLINICAL PATHOLOGY, 2011, 64 (08) :649-653

[5] Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations [J].

Berghmans, T. ;

Pasleau, F. ;

Paesmans, M. ;

Bonduelle, Y. ;

Cadranel, J. ;

Toth, I. Cs ;

Garcia, C. ;

Giner, V. ;

Holbrechts, S. ;

Lafitte, J. J. ;

Lecomte, J. ;

Louviaux, I. ;

Markiewicz, E. ;

Meert, A. P. ;

Richez, M. ;

Roelandts, M. ;

Scherpereel, A. ;

Tulippe, Ch. ;

Van Houtte, P. ;

Van Schil, P. ;

Wachters, C. ;

Westeel, V. ;

Sculier, J. P. .

EUROPEAN RESPIRATORY JOURNAL, 2012, 39 (01) :9-28

[6] Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas [J].

Boland, Jennifer M. ;

Erdogan, Sibel ;

Vasmatzis, George ;

Yang, Ping ;

Tillmans, Lori S. ;

Johnson, Michele R. Erickson ;

Wang, Xiaoke ;

Peterson, Lisa M. ;

Halling, Kevin C. ;

Oliveira, Andre M. ;

Aubry, Marie Christine ;

Yi, Eunhee S. .

HUMAN PATHOLOGY, 2009, 40 (08) :1152-1158

[7] Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). [J].

Camidge, D. R. ;

Bang, Y. ;

Kwak, E. L. ;

Shaw, A. T. ;

Iafrate, A. J. ;

Maki, R. G. ;

Solomon, B. J. ;

Ou, S. I. ;

Salgia, R. ;

Wilner, K. D. ;

Costa, D. B. ;

Shapiro, G. ;

LoRusso, P. ;

Stephenson, P. ;

Tang, Y. ;

Ruffner, K. ;

Clark, J. W. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

[8] Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer [J].

Camidge, D. Ross ;

Theodoro, Mariana ;

Maxson, DeLee A. ;

Skokan, Margaret ;

O'Brien, Tara ;

Lu, Xian ;

Doebele, Robert C. ;

Baron, Anna E. ;

Varella-Garcia, Marileila .

CANCER, 2012, 118 (18) :4486-4494

[9] Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment [J].

Camidge, D. Ross ;

Kono, Scott A. ;

Flacco, Antonella ;

Tan, Aik-Choon ;

Doebele, Robert C. ;

Zhou, Qing ;

Crino, Lucio ;

Franklin, Wilbur A. ;

Varella-Garcia, Marileila .

CLINICAL CANCER RESEARCH, 2010, 16 (22) :5581-5590

[10] Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma [J].

Christensen, James G. ;

Zou, Helen Y. ;

Arango, Maria E. ;

Li, Qiuhua ;

Lee, Joseph H. ;

McDonnell, Scott R. ;

Yamazaki, Shinji ;

Alton, Gordon R. ;

Mroczkowski, Barbara ;

Los, Gerrit .

MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) :3314-3322

← 1 2 3 4 5 6 7 →